Non-Opioid Pain Management Market Global Report 2026

The non-opioid pain management market size has grown strongly in recent years. It will grow from $44.93 billion in 2025 to $48.78 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to rising awareness of opioid addiction risks, increasing prevalence of chronic pain disorders, growing adoption of non-opioid analgesics, expansion of hospital-based pain management programs, increasing use of physical therapy and rehabilitation practices.

The non-opioid pain management market size is expected to see strong growth in the next few years. It will grow to $68.34 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing adoption of AI-based pain assessment tools, increasing investment in personalized medicine and genomics, expansion of digital health and remote patient monitoring, rising demand for non-invasive and drug-free therapies, integration of wearable and connected healthcare devices. Major trends in the forecast period include rising adoption of multimodal non-opioid therapies combining pharmacological and physical interventions, increasing use of digital therapeutics for chronic pain monitoring and management, growing preference for personalized pain treatment protocols based on patient profiling, expansion of minimally invasive and regenerative pain relief techniques, increasing integration of wearable devices for real-time pain tracking and rehabilitation support.

The rising prevalence of chronic pain conditions is expected to propel the growth of the non-opioid pain management market going forward. Chronic pain conditions are disorders that cause persistent or recurring pain lasting longer than three months and can negatively impact daily functioning and quality of life. Chronic pain conditions are increasing due to the rising aging population, as older individuals are more susceptible to developing long-term pain from age-related musculoskeletal and nerve disorders. Non-opioid pain management helps chronic pain conditions by reducing persistent pain and inflammation while improving mobility and daily functioning without the dependency risks associated with opioid medications. For instance, in February 2025, Arthritis Australia, an Australia-based non-profit organization, estimates that approximately 5.39 million Australians will be living with arthritis, representing a 31% increase since 2025. Therefore, the rising prevalence of chronic pain conditions is driving the growth of the non-opioid pain management market.

Major companies operating in the non-opioid pain management market are focusing on developing innovative solutions such as non-opioid oral analgesics to provide effective pain relief with reduced risk of addiction and fewer side effects compared to opioid-based therapies. Non-opioid oral analgesics are orally administered pain-relief medications used to manage mild to moderate pain without opioid compounds, helping reduce the risk of dependence while effectively treating conditions such as headaches, arthritis, musculoskeletal disorders, and post-operative pain. For instance, in January 2025, Vertex Pharmaceuticals Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic indicated for the treatment of moderate to severe acute pain in adults. The therapy works by selectively targeting NaV1.8 sodium channels in the peripheral nervous system, helping block pain signals before they reach the brain. This approval marked a significant advancement in non-opioid pain management by providing an effective alternative to opioid-based therapies.

In May 2025, Eli Lilly and Company, a US-based pharmaceutical company, acquired SiteOne Therapeutics Inc. for $1 billion. With this acquisition, Eli Lilly and Company aims to strengthen its non-opioid pain management pipeline by advancing innovative therapies that provide effective pain relief with lower risks of addiction and side effects associated with opioids. SiteOne Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company that offers non-opioid pain management treatments.

Major companies operating in the non-opioid pain management market are Johnson & Johnson; Pfizer Inc.; Bayer AG; Abbott Laboratories; Eli Lilly and Company; Boehringer Ingelheim; Teva Pharmaceutical Industries Ltd.; Haleon plc; Sun Pharmaceutical Industries Ltd.; Vertex Pharmaceuticals Incorporated; Perrigo Company plc; Aurobindo Pharma; Cipla Ltd.; Lupin Limited; Amneal Pharmaceuticals; Zydus Lifesciences; Pacira BioSciences Inc.; Alvogen; Heron Therapeutics; Hyloris Pharmaceuticals; Pierrel S.p.A.; Regenexbio.

North America was the largest region in the non-opioid pain management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-opioid pain management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-opioid pain management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-opioid pain management market consists of sales of nerve stimulators, pain relief patches, and radiofrequency ablation systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The non-opioid pain management market research report is one of a series of new reports that provides non-opioid pain management market statistics, including non-opioid pain management industry global market size, regional shares, competitors with a non-opioid pain management market share, detailed non-opioid pain management market segments, market trends and opportunities, and any further data you may need to thrive in the non-opioid pain management industry. This non-opioid pain management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.